Caroline A Heckman

List of Publications by Year
in descending order

139 papers	4,703 citations	196777 29 h-index	120465 65 g-index
147 all docs	147 docs citations	147 times ranked	8913 citing authors

#	Article	IF	Citations
1	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discovery, 2022, 12, 388-401.	7.7	73
2	The Peptideâ€“Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death. HemaSphere, 2022, 6, e687.	1.2	3
3	Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia. HemaSphere, 2022, 6, e701.	1.2	4
4	Bipartite network models to design combination therapies in acute myeloid leukaemia. Nature Communications, 2022, 13, 2128.	5.8	15
5	Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen. Cells, 2022, 11, 1574.	1.8	2
6	Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia. Blood, 2022, 140, 1891-1906.	0.6	19
7	CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia. Science Translational Medicine, 2022, 14, .	5.8	8
8	Review: Aminopeptidases in Cancer, Biology and Prospects for Pharmacological Intervention. Current Cancer Drug Targets, 2022, 22, .	0.8	3
9	Enrichment of cancer-predisposing germline variants in adult and pediatric patients with acute lymphoblastic leukemia. Scientific Reports, 2022, 12, .	1.6	3
10	RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses. Leukemia, 2021, 35, 1087-1099.	3.3	32
11	Prognostic significance of esterase gene expression in multiple myeloma. British Journal of Cancer, 2021, 124, 1428-1436.	2.9	18
12	Endogenous and combination retinoids are active in myelomonocytic leukemias. Haematologica, 2021, 106, 1008-1021.	1.7	11
13	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Science Advances, 2021, 7, .	4.7	28
14	Comparison of Structural and Short Variants Detected by Linked-Read and Whole-Exome Sequencing in Multiple Myeloma. Cancers, 2021, 13, 1212.	1.7	5
15	Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen. Cancers, 2021, 13, 1527.	1.7	29
16	Fusion gene detection by RNA sequencing complements diagnostics of acute myeloid leukemia and identifies recurring NRIP1-MIR99AHG rearrangements. Haematologica, 2021, , .	1.7	13
17	Next generation proteomics with drug sensitivity screening identifies sub-clones informing therapeutic and drug development strategies for multiple myeloma patients. Scientific Reports, 2021, 11, 12866.	1.6	8
18	Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. Npj Precision Oncology, 2021, 5, 71.	2.3	12

#	Article	IF	Citations
19	S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma. Frontiers in Cell and Developmental Biology, 2021, 9, 723016.	1.8	5
20	Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma. Blood Advances, 2021, 5, 4125-4139.	2.5	6
21	Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches. Proteomes, 2021, 9, 42.	1.7	6
22	Deep Immune Profiling in Multiple Myeloma at Diagnosis and Under Lenalidomide Maintenance Therapy. Blood, 2021, 138, 1597-1597.	0.6	0
23	Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database. Blood, 2021, 138, 608-608.	0.6	0
24	Preclinical Activity of Selective SYK Inhibitors, Entospletinib and Lanraplenib, Alone or Combined with Targeted Agents in Ex Vivo AML Models with Diverse Mutational Backgrounds. Blood, 2021, 138, 3356-3356.	0.6	2
25	Single Cell RNA Sequencing Identifies Potential Molecular Indicators of Response to Melflufen in Multiple Myeloma. Blood, 2021, 138, 1194-1194.	0.6	0
26	<i>Ex Vivo</i> Drug Sensitivity Testing to Predict Response to Venetoclax + Azacitidine in Acute Myeloid Leukemia: Interim Results of the Prospective Multicenter Phase II Venex Trial. Blood, 2021, 138, 228-228.	0.6	1
27	Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study. Blood, 2021, 138, 3438-3438.	0.6	0
28	Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation. Blood, 2021, 138, 4041-4041.	0.6	2
29	Phosphoproteomic Analysis of Primary Myeloma Patient Samples Identifies Distinct Phosphorylation Signatures Correlating with Chemo-Sensitivity Profiles in an Ex Vivo Drug Sensitivity Testing Platform. Blood, 2021, 138, 2666-2666.	0.6	2
30	FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML. Scientific Reports, 2021, 11, 23565.	1.6	6
31	Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. Haematologica, 2020, 105, 1527-1538.	1.7	19
32	A candid view of CANDOR. Lancet, The, 2020, 396, 147-148.	6.3	1
33	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. Leukemia, 2020, 34, 2780-2784.	3.3	6
34	Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. Leukemia, 2020, 35, 1964-1975.	3.3	35
35	MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. Journal of Hematology and Oncology, 2020, 13, 173.	6.9	91
36	Immunogenomic Landscape of Hematological Malignancies. Cancer Cell, 2020, 38, 380-399.e13.	7.7	109

#	Article	IF	Citations
37	Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition. Leukemia, 2020, 34, 3186-3196.	3.3	22
38	Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis. Cancers, 2020, 12, 1694.	1.7	13
39	Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Advances, 2020, 4, 546-559.	2.5	36
40	Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica, 2020, 105, 708-720.	1.7	99
41	Integration of Deep Multi-Omics Profiling Veals New Insights into the Biology of Poor-Risk Acute Myeloid Leukemia. Blood, 2020, 136, 39-40.	0.6	0
42	Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia. Scientific Reports, 2019, 9, 11796.	1.6	9
43	Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML. Leukemia, 2019, 33, 2548-2553.	3.3	25
44	Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. PLoS Computational Biology, 2019, 15, e1006752.	1.5	106
45	Making Sense of the Epigenome Using Data Integration Approaches. Frontiers in Pharmacology, 2019, 10, 126.	1.6	58
46	Hemap: An Interactive Online Resource for Characterizing Molecular Phenotypes across Hematologic Malignancies. Cancer Research, 2019, 79, 2466-2479.	0.4	23
47	Combined gene essentiality scoring improves the prediction of cancer dependency maps. EBioMedicine, 2019, 50, 67-80.	2.7	18
48	Next Generation Proteomics and Drug Sensitivity Resistance Testing Allow for the Identification of Distinct Sub-clones of Multiple Myeloma Patients. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e102.	0.2	0
49	A phase 2 study of carfilzomib plus elotuzumab plus dexamethasone for myeloma patients relapsed after 1-3 prior treatment lines. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e279-e280.	0.2	0
50	Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia. Leukemia, 2019, 33, 1360-1372.	3.3	40
51	Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting. Oncogene, 2019, 38, 3288-3300.	2.6	39
52	In Vitro and inVivo Activity of Melflufen in Amyloidosis. Blood, 2019, 134, 3100-3100.	0.6	2
53	Associations between Microrna Expression, Disease Progression and Ex Vivo Drug Response in Multiple Myeloma. Blood, 2019, 134, 3069-3069.	0.6	0
54	Germline Gene Aberrations Are Common in High-Risk Adult and Pediatric Acute Lymphoblastic Leukemia Patients. Blood, 2019, 134, 1472-1472.	0.6	0

#	Article	IF	Citations
55	Azacytidine Inhibits Megakaryopoiesis Via the Induction of Immunogenic RNA Species and Activation of Type-I Interferon Signaling. Blood, 2019, 134, 1280-1280.	0.6	0
56	Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 3002-3005.	0.6	0
57	Germline alterations in a consecutive series of acute myeloid leukemia. Leukemia, 2018, 32, 2282-2285.	3.3	24
58	Chimeric NUP98â€“NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 725-732.	0.6	5
59	Improving genomics-based predictions for precision medicine through active elicitation of expert knowledge. Bioinformatics, 2018, 34, i395-i403.	1.8	6
60	A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow. SLAS Discovery, 2018, 23, 687-696.	1.4	23
61	RUNX1 Mutations Identify an Entity of Blast Phase Chronic Myeloid Leukemia (BP-CML) Patients with Distinct Phenotype, Transcriptional Profile and Drug Vulnerabilities. Blood, 2018, 132, 4257-4257.	0.6	6
62	Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML. Blood, 2018, 132, 2763-2763.	0.6	1
63	A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines. Blood, 2018, 132, 1975-1975.	0.6	1
64	Multi-Parametric Single Cell Profiling Defines Distinct Drug Responses in Healthy Hematological Cell Lineages That Are Retained in Corresponding Malignant Cell Types. Blood, 2018, 132, 264-264.	0.6	5
65	Paradox-Breaker Pan-RAF Inhibitors Induce an AML-Specific Cytotoxic Response and Synergize with Venetoclax to Display Superior Antileukemic Activity. Blood, 2018, 132, 2210-2210.	0.6	2
66	Predictive Response Biomarkers for BET Inhibitors in AML. Blood, 2018, 132, 2749-2749.	0.6	2
67	Combined Targeting of BET Family Proteins and BCL2 Is Synergistic in Acute Myeloid Leukemia Cells Overexpressing S100A8 and S100A9. Blood, 2018, 132, 2634-2634.	0.6	2
68	Combining Next Generation Proteomics Platforms with Drug Sensitivity Resistance Testing AllowsÃ, Identification of Physiologically Distinct Sub-ClonesÃ, That Can Inform Therapeutic and Drug Development Strategies. Blood, 2018, 132, 1901-1901.	0.6	0
69	Eltrombopag Promotes Megakaryocyte Survival and Signaling in the Presence of Specific Cytotoxic Agents. Blood, 2018, 132, 3836-3836.	0.6	0
70	Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo. Blood, 2018, 132, 3975-3975.	0.6	0
71	Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer. European Urology, 2017, 71, 319-327.	0.9	74
72	Somatic <i>MED12</i> Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry. Human Mutation, 2017, 38, 269-274.	1.1	20

#	Article	IF	Citations
73	JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cellâ€"induced protection of AML. Blood, 2017, 130, 789-802.	0.6	90
74	Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. Blood Advances, 2017, 1, 2257-2268.	2.5	25
75	The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia. BMC Genomics, 2017, 18, 629.	1.2	42
76	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. Blood, 2017, 130, 854-854.	0.6	1
77	Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. Oncotarget, 2017, 8, 22606-22615.	0.8	13
78	Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing. Oncotarget, 2017, 8, 56338-56350.	0.8	35
79	The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains. Oncotarget, 2017, 8, 103731-103743.	0.8	19
80	Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget, 2017, 8, 97516-97527.	0.8	28
81	In Silico and Ex Vivo Drug Screening Identifies Dasatinib as a Potential Targeted Therapy for T-ALL. Blood, 2016, 128, 4029-4029.	0.6	0
82	Identification of Optimized Compound Combinations for the Treatment of NUP98-NSD1+ AML. Blood, 2016, 128, 4711-4711.	0.6	0
83	Simultaneous Monitoring of Drug Responses on Distinct Hematopoietic Cell Populations Allow Assessment of Direct and Indirect Cytotoxic Effects of Targeted Therapies. Blood, 2016, 128, 3515-3515.	0.6	0
84	A High-Throughput Biology Approach to Identify Novel Therapies Specifically Targeting AML Blasts and Leukemic Stem Cells. Blood, 2016, 128, 2755-2755.	0.6	0
85	Novel Mutations in Patients with Blast Crisis or Accelerated Phase Chronic Myeloid Leukemia. Blood, 2016, 128, 1924-1924.	0.6	0
86	Transcriptional Regulatory Landscape of TCF3-PBX1-Positive Leukemia and Novel Targeted Treatments. Blood, 2016, 128, 4077-4077.	0.6	0
87	Targeting of JAK/STAT Signaling to Reverse Stroma-Induced Cytoprotection Against BCL2 Antagonist Venetoclax in Acute Myeloid Leukemia. Blood, 2016, 128, 32-32.	0.6	14
88	DNA Damage Repair Pathway Alterations in Multiple Myeloma Predict Poor Prognosis, but Correlate with Sensitivity to IGF1R-PI3K-mTOR and HDAC Inhibitors. Blood, 2016, 128, 198-198.	0.6	0
89	Stromal-Derived Factors Modulate Ex Vivo Drug Responses of Primary Acute Myeloid Leukemia Cells. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S8-S9.	0.2	0
90	Stratification of Multiple Myeloma Patients Based on Ex Vivo Drug Sensitivity and Identification of New Treatments for Patients with High-Risk Relapsed/Refractory Disease. Blood, 2015, 126, 3006-3006.	0.6	0

#	Article	IF	Citations
91	BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo. Blood, 2015, 126, 2462-2462.	0.6	0
92	JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML. Blood, 2015, 126, 867-867.	0.6	0
93	Statistical detection of quantitative protein biomarkers provides insights into signaling networks deregulated in acute myeloid leukemia. Proteomics, 2014, 14, 2443-2453.	1.3	10
94	Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Scientific Reports, 2014, 4, 5193.	1.6	243
95	Landscape of Mutations in Relapsed Acute Myeloid Leukemia. Blood, 2014, 124, 2367-2367.	0.6	1
96	Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling. Blood, 2014, 124, 917-917.	0.6	0
97	Identification of Novel Therapeutic Strategies for NUP98-NSD1-Positive AML By Drug Sensitivity Profiling. Blood, 2014, 124, 2160-2160.	0.6	0
98	Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing. Blood, 2014, 124, 3505-3505.	0.6	0
99	The Use of RNA Sequencing to Identify Disease-Specific Gene Expression Signatures and Critical Regulatory Networks Across Hematologic Malignancies. Blood, 2014, 124, 2203-2203.	0.6	3
100	Integration of Ex Vivo Drug Testing and in-Depth Molecular Profiling Reveals Oncogenic Signaling Pathways and Novel Therapeutic Strategies for Multiple Myeloma. Blood, 2014, 124, 2046-2046.	0.6	3
101	Identification of Dual PI3K/mTOR and BCL2 Inhibitors for the Treatment of High Risk Multiple Myeloma. Blood, 2014, 124, 646-646.	0.6	0
102	Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse. Blood, 2014, 124, 1022-1022.	0.6	0
103	Drug Sensitivity Profiling Identifies Drugs for Targeting Constitutively Active Mutant STAT3 and Mutant STAT5B Positive Malignancies. Blood, 2014, 124, 1771-1771.	0.6	0
104	AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines. Blood, 2014, 124, 2163-2163.	0.6	1
105	A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses. Blood, 2014, 124, 3139-3139.	0.6	0
106	Landscape of Driver Lesions in Multiple Myeloma and Consequences for Targeted Drug Response. Blood, 2014, 124, 3351-3351.	0.6	0
107	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. Cancer Discovery, 2013, 3, 1416-1429.	7.7	334
108	Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. Blood, 2013, 121, 4541-4550.	0.6	252

#	Article	IF	Citations
109	Novel Activating STAT5B Mutations As Drivers Of T-ALL. Blood, 2013, 122, 3863-3863.	0.6	5
110	Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies. Blood, 2013, 122, 1668-1668.	0.6	0
111	Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing. Blood, 2013, 122, 3828-3828.	0.6	0
112	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. Blood, 2013, 122, 482-482.	0.6	0
113	High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1-Positive Leukemia. Blood, 2013, 122, 2719-2719.	0.6	0
114	Somatic<i>STAT3</i>Mutations in Large Granular Lymphocytic Leukemia. New England Journal of Medicine, 2012, 366, 1905-1913.	13.9	681
115	Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients. Experimental Hematology, 2012, 40, 705-714.e3.	0.2	16
116	Discovery of STAT5b Mutations and Small Subclones of STAT3 Mutations in Large Granular Lymphocytic (LGL) Leukemia. Blood, 2012, 120, 871-871.	0.6	2
117	High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. Blood, 2012, 120, 288-288.	0.6	1
118	Somatic PTPRT and ANGPT2 Mutations in Large Granulocyte Leukemia. Blood, 2012, 120, 1302-1302.	0.6	0
119	Comparison of solution-based exome capture methods for next generation sequencing. Genome Biology, 2011, 12, R94.	13.9	237
120	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. Blood, 2011, 118, 2487-2487.	0.6	0
121	Recurrent Missense Mutations in the STAT3 Gene in LGL Leukemia Provide Insights to Pathogenetic Mechanisms and Suggest Potential Diagnostic and Therapeutic Applications. Blood, 2011, 118, 936-936.	0.6	6
122	Phosphoprotein Profiling Predicts Response to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients. Blood, 2011, 118, 4427-4427.	0.6	0
123	Use of cancerâ€specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes and Cancer, 2010, 49, 1062-1069.	1.5	172
124	Functional Analysis of FLT4 Mutations Associated with Nonneâ€"Milroy Lymphedema. Journal of Investigative Dermatology, 2009, 129, 509-512.	0.3	7
125	Molecular Targeting of Lymphangiogenesis and Tumor Metastasis. , 2009, , 283-295.		0
126	The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis. Cancer Research, 2008, 68, 4754-4762.	0.4	104

#	Article	IF	Citations
127	Functional interaction of VEGFâ€C and VEGFâ€D with neuropilin receptors. FASEB Journal, 2006, 20, 1462-1472.	0.2	265
128	Histone Deacetylase Inhibitors Down-Regulate bcl-2 Expression and Induce Apoptosis in t(14;18) Lymphomas. Molecular and Cellular Biology, 2005, 25, 1608-1619.	1.1	227
129	CCAAT/Enhancer Binding Protein Î± (C/EBPÎ±) and C/EBPÎ± Myeloid Oncoproteins Induce Bcl-2 via Interaction of Their Basic Regions with Nuclear Factor-Îº B p50. Molecular Cancer Research, 2005, 3, 585-596.	1.5	50
130	C/EBPÎ± and C/EBPÎ± Myeloid Oncoproteins Induce Bcl-2 Via Interaction of Their Basic Regions with NF-ÎºB p50.. Blood, 2005, 106, 2992-2992.	0.6	10
131	HDAC2 Plays a Role in Protecting t(14;18) Lymphoma Cells from Apoptosis by Up-Regulation of Bcl-2.. Blood, 2004, 104, 1133-1133.	0.6	0
132	C/EBPÎ± and C/EBPÎ± Myeloid Oncoproteins Inhibit Apoptosis and Induce Bcl-2 Via DNA-Binding Dependent and Independent Mechanisms.. Blood, 2004, 104, 2561-2561.	0.6	0
133	Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells. Oncogene, 2003, 22, 7891-7899.	2.6	39
134	Critical elements of the immunoglobulin heavy chain gene enhancers for deregulated expression of bcl-2. Cancer Research, 2003, 63, 6666-73.	0.4	22
135	Allele-specific analysis of transcription factors binding to promoter regions. Methods, 2002, 26, 19-26.	1.9	5
136	NF-ÎºB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene, 2002, 21, 3898-3908.	2.6	174
137	Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene, 2001, 20, 240-251.	2.6	200
138	A-Myb Up-regulates Bcl-2 through a Cdx Binding Site in t(14;18) Lymphoma Cells. Journal of Biological Chemistry, 2000, 275, 6499-6508.	1.6	53
139	The WT1 Protein Is a Negative Regulator of the Normalbcl-2 Allele in t(14;18) Lymphomas. Journal of Biological Chemistry, 1997, 272, 19609-19614.	1.6	70